Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $100.38, for a total transaction of $2,007,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $77,069,756.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Monday, November 16th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $98.38, for a total transaction of $1,967,600.00.
- On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.58, for a total transaction of $2,191,600.00.
- On Thursday, October 8th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.40, for a total transaction of $2,188,000.00.
- On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00.
- On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.24, for a total transaction of $2,144,800.00.
- On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00.
Halozyme Therapeutics Stock Down 3.8%
Shares of Halozyme Therapeutics stock traded down $3.77 during trading hours on Monday, hitting $96.50. 2,088,290 shares of the company’s stock traded hands, compared to its average volume of 2,352,912. The stock has a 50 day simple moving average of $114.29 and a 200-day simple moving average of $85.63. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 13.50. The company has a market cap of $11.00 billion, a PE ratio of 18.07, a PEG ratio of 0.38 and a beta of 0.92. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $134.00.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.30 by $0.09. The business had revenue of $492.97 million for the quarter, compared to analysts’ expectations of $491.63 million. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The company’s revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.72 earnings per share. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on HALO shares. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. Citizens Jmp raised their price target on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the stock a “market outperform” rating in a research report on Friday, November 6th. Leerink Partners downgraded shares of Halozyme Therapeutics from an “outperform” rating to a “hold” rating and raised their price target for the stock from $110.00 to $117.00 in a research report on Friday, November 6th. Stifel Nicolaus set a $130.00 price target on shares of Halozyme Therapeutics in a research note on Friday, October 16th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Monday. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and an average price target of $108.18.
Check Out Our Latest Analysis on HALO
Hedge Funds Weigh In On Halozyme Therapeutics
Several large investors have recently modified their holdings of HALO. MidFirst Bank bought a new stake in Halozyme Therapeutics in the second quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics during the second quarter valued at approximately $28,000. Quantbot Technologies LP bought a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $30,000. CoreCap Advisors LLC lifted its holdings in Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 150 shares during the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $33,000. Institutional investors own 97.79% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Recommended Stories
- Five stocks we like better than Halozyme Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
